- Home
- EBON vs BCAB Comparison
EBON vs BCAB Comparison
Compare EBON & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBON | BCAB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 20.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EBON | BCAB |
|---|---|---|
| Price | $2.45 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 4.7K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.13 |
| 52 Week High | $5.90 | $1.43 |
Technical Indicators
Market Signals| Indicator | EBON | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 36.94 |
| Support Level | $2.30 | $0.13 |
| Resistance Level | $3.76 | $0.57 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 20.85 | 58.96 |
Price Performance
Historical ComparisonAbout EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.